Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows
About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.
Tomas Kauer - Moderator 
About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo. Read More
